Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Considerations for PIK3CA mutations: An interactive discussion

Date

02 May 2019

Session

Novartis - Industry Satellite Symposium: Innovation in HR+, HER2– advanced breast cancer and the emerging role of biomarkers

Presenters

Nicholas Turner

Authors

N.C. Turner

Author affiliations

  • Breast Unit, Royal Marsden and Institute of Cancer Research, SW3 6JJ - London/GB
More

Resources

Resources from the same session

Welcome and introduction

Presenter: Diana Lüftner

Session: Novartis - Industry Satellite Symposium: Innovation in HR+, HER2– advanced breast cancer and the emerging role of biomarkers

Resources:

Presentation

Webcast

The advancing role of PI3K inhibitors

Presenter: Peter Fasching

Session: Novartis - Industry Satellite Symposium: Innovation in HR+, HER2– advanced breast cancer and the emerging role of biomarkers

Resources:

Presentation

Webcast

Expanding the evidence base for CDK4/6 inhibitors

Presenter: Diana Lüftner

Session: Novartis - Industry Satellite Symposium: Innovation in HR+, HER2– advanced breast cancer and the emerging role of biomarkers

Resources:

Presentation

Webcast

Audience question & answer

Presenter: Diana Lüftner

Session: Novartis - Industry Satellite Symposium: Innovation in HR+, HER2– advanced breast cancer and the emerging role of biomarkers

Resources:

Presentation

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings